Bio-Techne (TECH) Q4 2026 earnings summary

Executive summary

• Organic revenue grew 3% year-over-year in Q4 FY2026 to $321.2M; full-year revenue was flat at $1.2B.

• GAAP EPS rose to $0.35 in Q4 from $(0.11) last year; adjusted EPS was $0.52, slightly down from $0.53.

• Announced acquisition agreement by Merck KGaA for $73/share, valuing the company at $11.3B.

Financial highlights

• Q4 net sales increased 1% to $321.2M; organic growth was 3%.

• Q4 GAAP operating income was $74.3M (23.1% margin), up from a loss last year.

• Full-year GAAP EPS was $1.16, up from $0.46; adjusted EPS was $1.93, up from $1.92.

• Adjusted operating margin for Q4 was 32.2%, up from 32.0% last year.

• Adjusted EBITDA for the year was $432M, up from $430M.

Outlook and guidance

• Progressing toward completion of the Merck KGaA acquisition, expected to create new opportunities for customers and employees.